RIVM has carried out additional research into the security of supply of diagnostic and therapeutic radionuclides for the Netherlands and into the effects of not building the PALLAS-reactor, the intended successor to the HFR.
Following the reports published in 2017 and 2018, the RIVM, the National Institute for Public Health and Environment, mapped out the market development and security of supply of medical isotopes in the Netherlands. Various conclusions are drawn, in which the importance of the PALLAS-reactor is endorsed.
“The European Commission has stated that one new reactor is needed to cover the demand. The initiative in the Netherlands for the replacement of the HFR (PALLAS) is stated as a candidate to increase the producing capacity.”
Update RIVM September 30 2019: “The SHINE-project is being built in America. This installation is an advanced new-build project for the production of, for example, molybdenum-99. We do not expect that the SHINE-concept will make it possible to make the entire range of reactor-produced medical radionuclides within decades. The SHINE-concept is therefore not a complete replacement for a reactor that produces medical radionuclides.”